Medication Tracking
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application 62/062,845, filed Oct 11, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,171,280 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 9,582,644 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 10,083,766 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 10,600,513 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 10,930,393 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 11,557,393 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| US 12,165,763 | Medication Tracking In force · Medium confidence | Bluesight, Inc. | In force | Medium confidence | ||
| US 12,494,283 | Medication Tracking In force · High confidence | Bluesight, Inc. | In force | High confidence | ||
| Application 19/380,847 | Medication Tracking Pending Not granted | Bluesight, Inc. | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
8 of these are in force and held by Bluesight, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.